Oncology and Hematology - Prova Education

Episodes 17-32 of 136

Case Application: Unlocking Relapsed/Refractory Myeloma With CELMoDs
Case Application: Unlocking Relapsed/Refractory Myeloma With CELMoDs
MinuteCE®
Case Application: Unlocking Relapsed/Refractory Myeloma With CELMoDs
1.00 program credit
- Joshua Richter, MD
- Sagar Lonial, MD, FACP
1.00 program credit
Mastering the Sequence: CELMoDs Across Treatment Lines
Mastering the Sequence: CELMoDs Across Treatment Lines
MinuteCE®
Mastering the Sequence: CELMoDs Across Treatment Lines
1.00 program credit
- Sagar Lonial, MD, FACP
- Noopur Raje, MD
1.00 program credit
Chairperson’s Perspective: Optimizing Perioperative Therapy in Early-Stage NSCLC: A Multidisciplinary Approach
Chairperson’s Perspective: Optimizing Perioperative Therapy in Early-Stage NSCLC: A Multidisciplinary Approach
CME/CE
Chairperson’s Perspective: Optimizing Perioperative Therapy in Early-Stage NSCLC: A Multidisciplinary Approach
0.25 credits
- Heather Wakelee, MD, FASCO
0.25 credits
Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage III/IV Melanoma
Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage III/IV Melanoma
MinuteCE®
Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage III/IV Melanoma
1.00 program credit
- Paolo A. Ascierto, MD
- Hussein Tawbi, MD, PhD
1.00 program credit
MinuteCE®
Innovations in Oncology Learning Center: From Guidelines to Practice: Melanoma
1.00 credit 10 episodes
- John M. Kirkwood, MD
- Paolo A. Ascierto, MD
- Hussein Tawbi, MD, PhD
- Sapna Patel, MD
1.00 credit 10 episodes
Clinical Implications of Neoadjuvant Therapy Guideline Updates in Resectable Melanoma
Clinical Implications of Neoadjuvant Therapy Guideline Updates in Resectable Melanoma
MinuteCE®
Clinical Implications of Neoadjuvant Therapy Guideline Updates in Resectable Melanoma
1.00 program credit
- John M. Kirkwood, MD
- Sapna Patel, MD
1.00 program credit
Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed Stage III Melanoma
Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed Stage III Melanoma
MinuteCE®
Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed Stage III Melanoma
1.00 program credit
- Paolo A. Ascierto, MD
- Hussein Tawbi, MD, PhD
1.00 program credit
Emerging and Practice Changing Data in Immunotherapy Strategies for Melanoma
Emerging and Practice Changing Data in Immunotherapy Strategies for Melanoma
MinuteCE®
Emerging and Practice Changing Data in Immunotherapy Strategies for Melanoma
1.00 program credit
- Sapna Patel, MD
- John M. Kirkwood, MD
1.00 program credit
Insights From Global Key Opinion Leaders on Regional Regulatory and Guideline Nuances to Optimize Melanoma Management
Insights From Global Key Opinion Leaders on Regional Regulatory and Guideline Nuances to Optimize Melanoma Management
MinuteCE®
Insights From Global Key Opinion Leaders on Regional Regulatory and Guideline Nuances to Optimize Melanoma Management
1.00 program credit
- Hussein Tawbi, MD, PhD
- Paolo A. Ascierto, MD
1.00 program credit
Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma
Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma
MinuteCE®
Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma
1.00 program credit
- Paolo A. Ascierto, MD
- Hussein Tawbi, MD, PhD
1.00 program credit
Clinical Data Prompting Guideline Updates for Subcutaneous ICIs in Melanoma
Clinical Data Prompting Guideline Updates for Subcutaneous ICIs in Melanoma
MinuteCE®
Clinical Data Prompting Guideline Updates for Subcutaneous ICIs in Melanoma
1.00 program credit
- Hussein Tawbi, MD, PhD
- Sapna Patel, MD
1.00 program credit
Data Driving Recent Guideline Updates in Neoadjuvant Therapy for Resectable Melanoma
Data Driving Recent Guideline Updates in Neoadjuvant Therapy for Resectable Melanoma
MinuteCE®
Data Driving Recent Guideline Updates in Neoadjuvant Therapy for Resectable Melanoma
1.00 program credit
- John M. Kirkwood, MD
- Sapna Patel, MD
1.00 program credit
Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed BRAF-Mutant Stage IV Melanoma
Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed BRAF-Mutant Stage IV Melanoma
MinuteCE®
Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed BRAF-Mutant Stage IV Melanoma
1.00 program credit
- Hussein Tawbi, MD, PhD
- Sapna Patel, MD
1.00 program credit
Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage IIB/IIC Melanoma
Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage IIB/IIC Melanoma
MinuteCE®
Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage IIB/IIC Melanoma
1.00 program credit
- Paolo A. Ascierto, MD
1.00 program credit
Community Clinic: Translating Data Into Action ─ Practical Strategies for Optimizing First-Line RCC Management
Community Clinic: Translating Data Into Action ─ Practical Strategies for Optimizing First-Line RCC Management
CME/CE
Community Clinic: Translating Data Into Action ─ Practical Strategies for Optimizing First-Line RCC Management
0.25 credits
- Robert J. Motzer, MD
- Elizabeth R. Plimack, MD, MS, FASCO
0.25 credits
Contrasting TROP2-Targeted ADCs in Breast Cancer Therapy
Contrasting TROP2-Targeted ADCs in Breast Cancer Therapy
CME/CE
Contrasting TROP2-Targeted ADCs in Breast Cancer Therapy
0.50 credits
- Kevin Kalinsky MD, MS
- Komal Jhaveri, MD, FACP
0.50 credits

2/7